To investigate the clinical implications of the SMAD4 status on radiotherapy resistance, we conducted IHC analyses of SMAD4 in tissue microarrays from 86 pancreatic ductal adenocarcinoma (PDAC) patients, comparing tumor tissues with adjacent normal tissues (Fig. 1A). The gene discussed is SMAD4; the disease is pancreatic ductal adenocarcinoma.